Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial

Published:2019-09 Issue:9 Volume:110 Page:2894-2904
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tamura Kenji¹^ORCID,Hasegawa Kosei²,Katsumata Noriyuki³,Matsumoto Koji⁴,Mukai Hirofumi⁵,Takahashi Shunji⁶,Nomura Hiroyuki⁷,Minami Hironobu⁸^ORCID

Affiliation:

1. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

2. Department of Gynecologic Oncology Saitama Medical University International Medical Center Saitama Japan

3. Department of Medical Oncology Nippon Medical School Musashikosugi Hospital Kanagawa Japan

4. Department of Medical Oncology Hyogo Cancer Center Hyogo Japan

5. Department of Breast and Medical Oncology National Cancer Center Hospital East Chiba Japan

6. Department of Medical Oncology The Cancer Institute Hospital of JFCR Tokyo Japan

7. Department of Obstetrics and Gynecology Keio University School of Medicine Tokyo Japan

8. Medical Oncology and Hematology Kobe University Hospital Kobe Japan

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14148

Reference22 articles.

1. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

2. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas

3. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer

4. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma

5. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacterial pneumonia during successful treatment of metastatic endometrial cancer with dostarlimab- case report and a literature review;2024-08-28

2. Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis;Frontiers in Oncology;2024-08-20

3. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

4. Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review;Clinical and Experimental Obstetrics & Gynecology;2024-07-11

5. Immunotherapy in Sarcoma: Current Data and Promising Strategies;American Society of Clinical Oncology Educational Book;2024-06